Get Integrated Data for Your Specialty and Interest Aresa
 
Category Select :
Items 1 ~ 20 of 985, Page 1 of 50
1. European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma - 07/29/2019
 MERCK
  Opinion Granted Based on Significant Overall Survival Benefit for KEYTRUDA in Combination with Axitinib Compared to Sunitinib in Phase 3 KEYNOTE-426 Trial
2. WHO recommends dolutegravir as preferred HIV treatment option in all populations - 07/22/2019
 WHO
3. FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available - 07/17/2019
 MERCK
4. KIDNEY PATIENTS, CARE PARTNERS INVITED TO SUBMIT IDEAS AND INNOVATIONS FOR NATIONAL PRIZE COMPETITION - 07/11/2019
 American Society of Nephrology (ASN)
  U.S. Department of Health and Human Services, American Society of Nephrology, and the National Kidney Foundation announce new Patient Innovator Challenge
5. WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access - 07/09/2019
 WHO
  New essential medicines and diagnostics lists published today
6. DOES HYPERTENSION POSE A HEALTH RISK TO OLDER ADULTS WHO WISH TO DONATE A KIDNEY? - 06/25/2019
 American Society of Nephrology (ASN)
  Study finds higher rates of kidney failure in donors with high blood pressure.
7. In the face of slow progress, WHO offers a new tool and sets a target to accelerate action against antimicrobial resistance - 06/18/2019
 WHO
8. New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting - 05/15/2019
 MERCK
  First-Time Data from POLO Trial Evaluating LYNPARZA ® (olaparib) in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press Program / KEYTRUDA ® (pembrolizumab) Five-Year Survival Data in Advanced Non-Small Cell Lung Cancer (NSCLC) from KEYNOTE-001 Trial in ASCO Press Program / Overall Survival Data for KEYTRUDA in Metastatic Renal Cell Carcinoma (RCC), Recurrent/Metastatic Head and Neck Cancer and Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer
9. FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) - 04/22/2019
 MERCK
  Approval Based on Results of KEYNOTE-426, Where KEYTRUDA in Combination With Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib
10. FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam) - 02/05/2019
 MERCK
11. FDA statement from Commissioner announcing efforts to improve the quality of the information used to assess the effectiveness of REMS programs in supporting the safe use of medications - 01/24/2019
 U.S. FOOD & DRUG ADMINISTRATION
  Risk Evaluation and Mitigation Strategy (REMS)
12. Personalized Treatment Benefits Kidney Cancer Patients - 01/15/2019
 Radiological Society of North America
  Patients who have risk factors for worsening kidney disease may benefit from personalized treatment plans / Researchers constructed a simulation model to assess the impact of different treatment approaches in patients with small renal tumors. /
13. Almost 4% of Cancers Worldwide Due to Excess Body Weight - 12/19/2018
 American Cancer Society
  Excess body weight is responsible for an estimated 544,300 cancers, which is about 3.9% of all cancers in the world, according to research by the American Cancer Society, Imperial College London, and the Harvard T.H. Chan School of Public Health.
14. FDA Approves Smart Programmer for the InterStim System - 12/17/2018
 Medtronic
  Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence
15. Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on transformative new steps to modernize FDA’s 510(k) program to advance the review of the safety and effectiveness of medical devices - 11/26/2018
 U.S. FOOD & DRUG ADMINISTRATION
  Modernizing the 510(k) Pathway“Safety and Performance Based Pathway” / Promoting Greater Transparency and Post-Market Surveillance
16. Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs - 11/16/2018
 U.S. FOOD & DRUG ADMINISTRATION
17. AMA President Outlines Efforts to Attack Dysfunction in Health Care - 11/14/2018
 American Medical Association
18. Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication - 11/08/2018
 Medtronic
  FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension
19. New $15 Million Initiative to Further Reimagine Physician Training - 10/30/2018
 American Medical Association (AMA)
  New AMA Reimagining Residency initiative is aimed at transforming residency training to ensure physician well-being and improved patient safety.
20. The overlooked benefits of medical scribes - 10/26/2018
 American Medical Association (AMA) News by Andis Robeznieks
  It''s a given that using medical scribes will reduce data-entry time for physicians. But the myriad benefits this produces for patients and physicians are now being quantified by emerging research.
<<  <  [1[2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  >  >>
 


Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email : medalls@medalls.com